Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk through free LDL-C testing, public-private partnerships, and implementation science initiatives—all aimed at cutting CV events in half by 2030.
Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.
Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.
Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.
Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across primary care, cardiology, and rehabilitation are critical to improving outcomes and preventing care gaps for cardiovascular patients.
Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in its strategic plans amid recent market challenges.
Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.
Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses how new findings highlight the need for simplified decision-making in lipid management and a stronger focus on achieving LDL-C targets to help prevent heart attacks and strokes.
Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.
Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.
The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.
The protection and privacy of healthcare data is a massive hurdle for the new technology to overcome.
Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.
The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who received the Ixchiq chikungunya vaccine.
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses new real-world data showing that most high-risk cardiovascular patients in the US are not starting or intensifying lipid-lowering therapy—and few are achieving guideline-recommended LDL-C targets.
The campaign promotes women to have conversations with their family members about heart health history.
Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
Groups like PhRMA and the HDA issued statements explaining their stance of the drug-pricing policy.
Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how repurposing GLP-1s and psychedelics for addiction treatment introduces unexpected patent challenges, liability concerns, and complex state-by-state regulatory hurdles.
Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.
The 700,000 square-foot facility is expected to create 400 high-wage manufacturing jobs once operational.
The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the world.
The President plans to sign an executive order on Monday morning to enforce the trade clause.
Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing $250 million to pharmaceutical innovation and workforce development through its extended partnership with Purdue University.
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.
Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how regulatory, patent, and reimbursement challenges are slowing venture investment in GLP-1 and psychedelic addiction therapies.
